hotspot -WSS

hotspot

author：focus 2025-09-06 01:41:22 - browse：854

Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for patients with cirrhosis caused by NASH, the most advanced and life-threatening stage of the fatty liver disease.

While the study’s primary goal of improving liver fibrosis, or scarring, was not achieved, the Akero drug, called efruxifermin, outperformed placebo by 10 percentage points. The drug also resolved NASH symptoms, including reductions in liver fat and inflammation, and improved other markers of the disease.

“These are the best data reported to date for any NASH drug in this patient population,” said Kitty Yale, Akero’s chief development officer. “We missed the primary endpoint. We understand that, but there’s actually a lot of hope when you look at the totality of the data.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Following judge's order, DOJ releases slightly less

explore

WSS

New brain studies show LSD's effects on the brain in full color

FDA clears AI tool for detecting skin cancer

Former New York Mayor de Blasio and wife announce separation, but not divorce

Princess Kate attends Wimbledon with Roger Federer: See the photos

The leaders of Italy and Poland say European Union should focus on stopping migration

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Wikipedia

hotspot

knowledge

Peter Hotez and the public health issue of online harassment

5 shark bites reported on Long Island as officials deploy surveillance drones

In age of alternative facts, a scholarly course on calling out crap

Think you might have Covid

George Santos makes 1st court appearance after pleading not guilty to 13 counts

EU moves toward latest gene techniques in food production to counter climate change, shortages

Bright Health sells Medicare Advantage business to Molina

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Bright Health sells Medicare Advantage business to Molina

Condition critical? Britain's beloved but battered National Health Service turns 75

focus

Elizabeth Holmes banned from government health programs

How digital therapeutics firms are pivoting after Pear's bankruptcy

Man pleads guilty to raping Ohio girl who ended up traveling across state lines for abortion

Parkinson’s finding may lead to tests and, someday, treatments

Think you might have Covid

AI generated plenty of interest at JPM but not a lot of trust

knowledge

hotspot

explore

hotspot